Search
Search
AVS: 2019
Show Description +
Sophie Bakri, MD, reviews her talk from Duke AVS 2019 on intervention in diabetic retinopathy (DR). Dr. Bakri discusses the results of both the PANORAMA and the RISE/RIDE studies to illustrate the need for careful patient selection when treating nonproliferative DR. She says that while it has been shown that anti-VEGF treatment can slow the progression of DR, the potential for loss to follow-up—and the negative effects of anti-VEGF therapy cessation—must be thoughtfully considered when deciding whether or not to initiate treatment in patients with nonproliferative DR.
Posted: 4/26/2019
Sophie Bakri, MD, reviews her talk from Duke AVS 2019 on intervention in diabetic retinopathy (DR). Dr. Bakri discusses the results of both the PANORAMA and the RISE/RIDE studies to illustrate the need for careful patient selection when treating nonproliferative DR. She says that while it has been shown that anti-VEGF treatment can slow the progression of DR, the potential for loss to follow-up—and the negative effects of anti-VEGF therapy cessation—must be thoughtfully considered when deciding whether or not to initiate treatment in patients with nonproliferative DR.
Posted: 4/26/2019
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AVS: 2019.
Please log in to leave a comment.